Tesamorelin acetate, also known under the branded name of Egrifta, is a manufactured form of growth-hormone-releasing hormone (GHRH) predominantly used in the treatment of HIV-associated lipodystrophy. Tesamorelin acetate is a manufactured peptide comprised of all 44 amino acids of human GHRH as well as a trans-3-hexenoic acid group. Structurally, tesamorelin acetate is created through the attachment of a hexenoyl moiety, which is a C6 chain holding a double bond at position 3, to the accompanying tyrosine residue at the N-terminal of the molecule. Tesamorelin acetate stimulates the body's growth hormone secretion, and thus increases and helps to temporarily maintain IGF-1 and IGFBP-3 levels.
Tesamorelin acetate is delivered as a sterile, preservative-free lyophilized powder designed for subcutaneous injection. Reconstitution must occur before use. Reconstitute with sterile water for injection, USP. Vials typically contain 2 mg of tesamorelin as the free base (2.2 mg tesamorelin acetate, anhydrous) and a percentage of inactive ingredient— mannitol, USP. The generally recommended dose is 2 mg injected subcutaneously once a day. Decisions regarding a particular patient's individual dosage will be strictly predicated upon the patient's current medical/health status, current medications, medical history, family history, age, weight, and gender.
Some patients may experience some mild or severe side effects listed below.
"It is rare to find health professionals who are so willing to educate the patient on what they need to know."